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A 100 years have gone by since James Stephen Ewing 
published the first edition of ‘Neoplastic Diseases: A Text-
Book on Tumours,’ in 1919.[1] This landmark publication 
formally laid down the foundations of the discipline of 
oncology. James Ewing’s contribution to modern-day 
oncological diagnosis and research has been immense. He 
cofounded the American Association for Cancer Research 
in 1907 and was its first president. He was also the first 
Professor of Pathology at Cornell and later became the 
director of Memorial Sloan-Kettering Cancer Center. In 
1921, Ewing reported a new bone cancer and called it ‘a 
diffuse endothelioma of the bone.’ This discovery was 
later named after the maestro himself and since has been 
known to the world as Ewing’s sarcoma.[2,3]
Ewing’s sarcoma is a small, round, blue cell malignancy 
arising from bone or soft tissue and most commonly 
affects adolescents and young adults. Although the 
histogenesis remains debatable, the genetic abnormality 
is characterised by the pathognomonic EWSR1-ETS gene 
fusions (EWSR1-FLI1) which serve as the oncogenic 
transcription factor, driving this cancer.[4]
Globally, Ewing’s sarcoma is the third most common 
primary malignant bone tumour, preceded by multiple 
myeloma and osteosarcoma and is the most frequent type 
in population under the age of 15 years.[5] In Pakistan, this 
tumour is most prevalent under the age of 30 years with 
a predilection toward males and is found commonly in 
vertebrae, tibia, femur and the hip bone.[6] Local studies 
show that Ewing’s sarcoma is the second most prevalent 
aggressive bone and/or soft-tissue sarcoma in children, 
following rhabdomyosarcoma with pelvis, femur and ribs 
being the most common sites.[7,8]
Till today, the strongest predictor of survival for Ewing’s 
sarcoma is the stage at the time of initial diagnosis, thus 
suggesting that the earlier the detection, the favourable 
the outcomes. The diagnostic algorithm consists 
of magnetic resonance imaging and/or computed 
tomography (CT) scan of the primary site, chest CT 
scan, positron-emission tomography and/or bone 
scan and bone marrow biopsy. However, as molecular 
diagnostic techniques are refined, it is evident that 
a significant proportion of patients with apparently 
localised disease may have micrometastatic involvement 
in the bone marrow.[9]
The treatment regimen consists of aggressive 
chemotherapy with radiation and surgery. With the 
establishment of this multimodal approach, there has 
been an improvement in the survival rate from 20% 
in the non-chemotherapy era to 70% in modern times. 
Worldwide, three strategies are commonly used for 
chemotherapy. In North America, the combination 
of vincristine, doxorubicin and cyclophosphamide, 
alternating with ifosfamide and etoposide used in a time 
intense schedule, is considered the standard. In Europe, 
there is predilection toward the use of vincristine, 
ifosfamide and doxorubicin and etoposide (VIDE) as 
the initial chemotherapy regimen. In adult patients, 
the regimen VIDE has also been used including the 
use of dactinomycin in some regimens. To minimize 
therapy related toxicity, risk stratification is used in 
Euro-Ewing-99 protocol dividing patients into three risk 
groups based on tumour volume, presence and pattern of 
metastatic disease and histologic response to induction 
therapy. The treatment is then modified based on these 
three risk groups.[10]
Amid the advances in treatment, a quarter of the patients 
will experience recurrence, majority of them within 2 years 
of initial diagnosis and with more than two third relapses 
occurring at distant sites most commonly the lungs and/
or bones. These recurrences bear poor outcomes, despite 
the progress made in the management of patients with 
localised ES, patients with recurrent or metastatic disease 
have very few options. Treatment intensification, often 
including consolidation with high-dose chemotherapy 
and autologous hematopoietic stem cell rescue, has not 
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proven to improve survival and has shown no benefit over 
standard chemotherapeutic regimens.[10]
The enhanced understanding of Ewing’s pathophysiology 
has enabled the introduction of more selective, effective, 
and less toxic ‘targeted’ agents for antitumor activity. The 
EWSR1-FLI1 target genes are very specifically expressed 
in Ewing’s sarcoma relative to normal tissues, and hence, 
experimental immunotherapeutic interventions have been 
targeted at this signalling pathway to achieve favourable 
outcomes. Biochemical evaluation has shown a high 
expression rate of insulin-like growth factor 1 receptor 
(IGF-1R) on the surface of the Ewing’s sarcoma tumour 
cells which has been hypothesised to drive tumour growth. 
Hence, ganitumab (an IGF-1R antibody) is being used in 
conjunction with conventional chemotherapy for patients 
with newly diagnosed metastatic Ewing’s sarcoma.[11]
Extensive research is underway in an attempt to find 
predictive biomarkers for early diagnosis and specific 
prompt treatment of Ewing’s sarcoma. Among these 
biomarkers for antibody-directed therapy are placenta 
growth factor, which may be implicated in invasiveness 
and metastatic potential of Ewing’s sarcoma and poly 
ADP-ribose polymerase 1, which has been shown to 
exponentially increase in Ewing’s tumour and carry 
a positive feedback loop with the EWS-FLI1 fusion 
transcript. The exciting new insights in immunotherapy of 
Ewing’s sarcoma and other paediatric sarcomas introduce 
the novel concept of integrating antibody-based and cell-
based immunotherapy into an overall treatment strategy.[12]
The Western world has benefitted massively with the 
increased knowledge and novel therapeutic regimens; 
however, the low- and middle-income countries, where the 
large bulk of this cancer is prevalent, still have not gained 
much. The success of therapy is based on multimodal 
approach and interdisciplinary efforts of oncologist, 
surgeons, radiation oncologists, pathologist and radiologist 
in effectively treating these solid tumours and sarcomas.[13] 
With scarce health-care resources and inadequate finances, 
there is an inability to accumulate all the required expertise 
in an attempt to cater to large populations in the low 
socioeconomic countries such as Pakistan.
There are limited data available on the long-term survival of 
Ewing’s sarcoma patients managed in Pakistan. However, 
unpublished data (abstracts presented) from two paediatric 
oncology centres in Karachi show that there are at least 
60% overall survival rates for localised Ewing’s disease, 
but this is limited to patients who complete their treatment 
according to standard guidelines and who reached paediatric 
oncology centres where oncologist, surgeons and radiation 
oncologist could give treatment in a multidisciplinary 
approach. Among the issues faced in Pakistan, the most 
important factors influencing poor outcomes are late 
referrals, followed by inadequate diagnosis and treatment.[14]
Perhaps, one of the most significant barriers in the 
advancement of therapy is the lack of cancer registries at 
national level which makes it difficult to gauge the burden of 
disease and short-/long-term outcomes.[15] The way forward 
is to utilize the hospital-based registries and provincial data 
to form minimum diagnostic and therapeutic guidelines, 
tailored to the needs of our own population. This includes 
deciding the chemotherapy regimen to accommodate the 
needs of our community and exploring surgical innovations 
to accommodate local needs.
In conclusion, there has been tremendous progress in 
understanding the pathophysiology, therapy and diagnosis 
of Ewing’s sarcoma in the past 100 years. The next 
decade will be an era of ‘precision medicine,’ with each 
individual being treated, based on his/her own risks and 
desired outcomes. A lot of work still needs to be done 
in developing ‘cure,’ especially in areas of metastatic 
and recurrent disease. Being a developing nation with 
double burden of disease, we have to start from scratch 
and strengthen our basic skills with specific focus on 
spreading awareness, appropriate referrals, capacity 
building, supportive care and proper documentation, 
including the advent of national disease registries and 
national protocols.
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